There are many technologies in the field of precision oncology (genomic profiling, in vitro testing, in silico modeling and others) that can give insight into which types of therapies might lead to a positive clinical response. In fact, these tools are complimentary to the functional oncology testing we do at Certis because they can help narrow down which therapies to test in an individual’s personalized mouse avatars, but they aren’t a necessity for YourPDX testing. The patient-derived xenograft orthotopic models we use for functional oncology testing closely recapitulate (repeat) human tumor development, closely mimic the behavior of cancer in their human counterparts and have the potential to better reflect the range of mutations and genetic background present in human cancers.1
References: 1 Mattar M, et al. Establishing and Maintaining an Extensive Library of Patient-Derived Xenograft Models. Front Oncol. 2018;8:19. Published 2018 Feb 19.